---
title: Research on the Effect and Mechanism of Aerobic Exercise on PD
nct_id: NCT04651140
overall_status: UNKNOWN
phase: NA
sponsor: The First Hospital of Jilin University
study_type: INTERVENTIONAL
primary_condition: "Parkinson's Disease"
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04651140.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04651140"
ct_last_update_post_date: 2021-01-05
last_seen_at: "2026-05-12T06:50:22.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Research on the Effect and Mechanism of Aerobic Exercise on PD

**Official Title:** Research on the Effect and Mechanism of Aerobic Exercise on Parkinson's

**NCT ID:** [NCT04651140](https://clinicaltrials.gov/study/NCT04651140)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** The First Hospital of Jilin University
- **Conditions:** Parkinson's Disease, Physical Exercise
- **Start Date:** 2020-10-13
- **Completion Date:** 2021-10-30
- **CT.gov Last Update:** 2021-01-05

## Brief Summary

This trial is expected to recruit patients with primary Parkinson's disease and give them four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism

## Detailed Description

This trial is expected to recruit patients with primary Parkinson's disease who are distributed into tremor group and stiff group and give them the same kind of four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism

## Eligibility

- **Minimum age:** 55 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Participants were diagnosed primary PD according to the 2015 MDS diagnostic criteria
* Participants are between 55 and 65 years old

Exclusion Criteria:

* Severe heart
* liver dysfunction
* kidney dysfunction
* severe cognitive dysfunction
* severe anxiety and depression
* history of mental illness
* history of cerebral infarction or ischemic attack in the past three months
* acute myocardial infarction or acute coronary in the past three months
* Parkinson's Pulse syndrome
* medication history (drugs that improve blood circulation in the brain and increase the excitability of the nervous system)
```

## Arms

- **Tremor group** (ACTIVE_COMPARATOR) — Participants in the tremor group have tremor as the main clinical manifestation
- **Stiff group** (ACTIVE_COMPARATOR) — Participants in the tremor group have stiff as the main clinical manifestation

## Interventions

- **aerobic exercise** (BEHAVIORAL) — Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks

## Primary Outcomes

- **Movement Disorder Society-United Parkinson's Disease Rating Scale (MDS-UPDRS)** _(time frame: changes of MDS-UPDRS score from baseline at four weeks)_ — to assess the motor and nonmotor function of PD,0-200 scores,the higher scores mean lower function
- **Montreal Cognitive Assessing(MoCA) score** _(time frame: changes of MoCA score from baseline at four weeks)_ — to assess the cognitive function of PD,0-30 scores,the higher scores mean better function
- **The Epworth Sleeping Scale(ESS)** _(time frame: changes of ESS score from baseline at four weeks)_ — to assess the degree of drowsiness, 0-24 scores, the higher scores mean severe drowsiness
- **Non-Motor Symptom Scale (NMSS)** _(time frame: changes of NMSS score from baseline at four weeks)_ — to assess the non-motor of PD , 0-120 scores, the higher scores mean severe non-motor damage

## Secondary Outcomes

- **cerebral blood variation by Head MRI** _(time frame: changes of the cerebral blood from baseline at four weeks)_
- **cerebral blood flow velocity** _(time frame: changes of the cerebral blood flow velocity from baseline at four weeks)_
- **the level of arterial blood pressure** _(time frame: changes of the arterial blood pressure from baseline at four weeks)_
- **the concentration of microRNA in peripheral blood by gene chip** _(time frame: changes of microRNA from baseline at four weeks)_

## Locations (1)

- FirstJilinU, Changchun, China

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.firstjilinu|changchun||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04651140.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04651140*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*